In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ashley Yeo

Executive Editor, MTI; Medtech Editor, In Vivo

London, UK

Ashley has reported on health care market issues with Citeline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).

Latest From Ashley Yeo

The E in ESG: Philips Drives For Science-Based Targets In Carbon Zero Challenge

With a product mix that includes high energy consumption imaging, capital equipment and personal health care, Philips has a unique spectrum of challenges in driving low carbon health care. Nevertheless, it has set the bar high in environmental sustainability goals, and is pressing suppliers to follow its lead.

Leadership Sustainability

Switzerland: US FDA’s Medtech Can Bridge Innovation Gap Left By MDR

Setting the patient safety bar too high will likely have the opposite effect in the case of the EU MDR. So believes the medtech industry in Switzerland, where work has begun at government level to pave the way for Swiss patients to have access to US FDA-approved medtech.

Switzerland Regulation

Podcast: German Hospital Reform Ushers In A Reimbursement ‘Revolution’

Germany is introducing a new system of paying for inpatient care, whereby funds will be allocated both to diagnosis related groups and to a provisional pot from which funds will be distributed according to the type of care delivered. In this podcast with Medtech Insight, Gabriel Flemming of Germany Trade & Invest explains what it all means for medtech.

Germany Market Access

Released: Germany’s Digital Strategy Will Transform Health And Care

An intense period of work overseen by Germany’s health ministry has culminated in the release of a new digital health care strategy. Germany now has a clear direction for how care will be transformed, says e-health chief Sebastian Zilch.

Germany Policy

Resilience, ‘Lessons Learned’ Must Be COVID Legacy In Germany

COVID-19 threat is abating and control measures easing, but government commitments made at height of pandemic to forearm against future health care emergencies should not be abandoned, says German Advisory Council on Health and Care and the IVD industry.

Consumer Coronavirus COVID-19

Innovation Adoption Is Key UK Challenge Says MedTech Directorate

The UK’s MedTech Directorate is pressing ahead with 16 separate initiatives under its recently issued medtech strategy. It all adds to the sense that 2023 will be a major year for UK medtech.

United Kingdom Policy
See All
UsernamePublicRestriction

Register